The investigators looked at 41 commonly used drug categories and assessed 1,883 faecal samples from a population-based healthy cohort, patients with inflammatory bowel disease (IBD), and patients with irritable bowel syndrome (IBS) intermixed with healthy controls. The researchers compared the profiles based on taxonomic characteristics and metabolic functions of medication users to non-medication users, looking at the effect of single medication use and then combined medication use. Among the drug categories, the researchers found that those with the biggest impact on the microbiome include proton pump inhibitors (PPIs), which are taken by >11% of the European population. PPIs are used to treat dyspepsia, peptic ulcers, in the eradication of H. Pylori, gastro-reflux, as well as Barrett's oesophagus. Similarly, metformin, commonly used as a treatment for Type 2 diabetes, affected the gut microbiome significantly. Not surprisingly, antibiotics, taken by 34% of the European population each year, made it to the top modulator drug categories. Finally, laxatives also restructured the taxonomy and metabolism of the gut microbiome.
Notable findings were that the gut microbiota of PPI users showed increased abundance of upper gastrointestinal tract bacteria and increased fatty acid production, while metformin users had higher levels of the potentially harmful bacteria E. coli.
The researchers also found that an additional 7 drug categories were associated with significant changes in bacterial populations in the gut. SSRI-antidepressant use in patients with IBS was associated with excessive levels of the potentially harmful bacteria species Eubacterium ramulus. The use of oral steroids was associated with high levels of methanogenic bacteria which has been associated with weight gain and obesity.
The authors concluded that the changes observed as a result of common medication use likely increase the risk of intestinal infections, obesity, and other serious conditions and disorders linked to the gut microbiome in the general population, with specific risks being increased in patients with a digestive disorder such as IBD or IBS.
- Vich Vila A et al. Impact of 41 commonly used drugs on the composition, metabolic function and resistome of the gut microbiome. UEG Week Barcelona, Catalonia, Spain, October 19-23, 2019, Abstract OP334.
Posted on
Previous Article
« Digital single-operator cholangioscopy more sensitive than endoscopic retrograde cholangiopancreatography Next Article
Subcutaneous ustekinumab as maintenance therapy in UC »
« Digital single-operator cholangioscopy more sensitive than endoscopic retrograde cholangiopancreatography Next Article
Subcutaneous ustekinumab as maintenance therapy in UC »
Table of Contents: UEGW 2019
Featured articles
Interview with UEG President Prof. Paul Fockens
Upper GI Disorders
Locally active corticosteroid promising in eosinophilic oesophagitis
First-in-human radiofrequency vapor ablation in Barrett’s oesophagus
Irritable Bowel Syndrome
Faecal microbiota transplantation is effective for irritable bowel syndrome
Human milk oligosaccharides improve IBS symptoms
Inflammatory Bowel Disease
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
Decreased microvilli length in CD patients
Phase 2 data shows benefit for mirikizumab in CD patients
Subcutaneous ustekinumab as maintenance therapy in UC
First evidence of long-term efficacy of ABX464 in ulcerative colitis
New treatment may reverse coeliac disease
IBD prevalence 3 times higher than estimated and expected to rise
Microbiome and Microbiota
Early stages of gastric metaplasia: molecular profiling
Plant-based foods and Mediterranean diet associated with healthy gut microbiome
Antibiotic resistance in H. pylori has doubled over last 20 years
Pancreatitis
New model predicts recurrence of acute biliary pancreatitis
Hepatology
Restrictive strategy for cholecystectomy selection does not reduce pain, but does reduce surgery
β-blockers may halt cirrhosis progression: PREDESCI trial
Obeticholic acid prevents liver fibrosis from NASH
Oncology
Metal stents are better than plastic for endoscopic biliary drainage
Ramosetron relieves low anterior resection syndrome
Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit
Endoscopy
EUS-guided histological specimens from the pancreatic cyst wall
Digital single-operator cholangioscopy more sensitive than endoscopic retrograde cholangiopancreatography
New single-use duodenoscope well-liked by endoscopists
Related Articles
October 23, 2019
Subcutaneous ustekinumab as maintenance therapy in UC
October 23, 2019
Half of common medications wreak havoc on gut microbiome
October 23, 2019
IBD prevalence 3 times higher than estimated and expected to rise
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com